NASDAQ:NRIX

Nurix Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy NRIX

*Your capital is at risk

$15.48

-0.89 (-5.44%)

At Close: Jun 03, 2026

Nurix Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 3.23. In total, the insiders bought 1.58M and sold 142.63K NRIX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	3.23
● Buy	1.58M shares
● Sell	142.63K shares
77% Buy Activity Strong Negative Correlation
Buy Signal Medium Confidence Feb 10, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (77% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 02, 2026 Buy	Common Stock M-Exempt	Ring Christine Chief Legal Officer	Officer	3 422 Value: $6K
Jun 02, 2026 Sell	Common Stock S-Sale	Ring Christine Chief Legal Officer	Officer	8 148 Value: $135.3K
Jun 02, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Ring Christine Chief Legal Officer	Officer	3 422 Value: $6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Silva Paul M Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Saltzman Edward C Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Reinsdorf Judith A Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Kapur Anil Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Dansey Roger D Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Baynes Roy D. Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Gregory Julia P Director	Director	31 250 Value: $495.6K
May 15, 2026 Buy	Director Stock Option (right to buy) A-Award	Lacey David L. Director	Director	31 250 Value: $495.6K
May 05, 2026 Sell	Common Stock S-Sale	Van Houte Hans Chief Financial Officer	C-Suite Officer	13 473 Value: $223.3K
May 05, 2026 Sell	Common Stock S-Sale	Van Houte Hans Chief Financial Officer	C-Suite Officer	582 Value: $10K
May 04, 2026 Sell	Common Stock S-Sale	Ring Christine Chief Legal Officer	Officer	8 148 Value: $138.2K
May 01, 2026 Sell	Common Stock S-Sale	Ring Christine Chief Legal Officer	Officer	5 394 Value: $90.4K
Apr 30, 2026 Buy	Common Stock M-Exempt	Hansen Gwenn Chief Scientific Officer	Officer	2 000 Value: $33.4K
Apr 30, 2026 Sell	Common Stock S-Sale	Hansen Gwenn Chief Scientific Officer	Officer	3 214 Value: $53.5K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Ring Christine Chief Legal Officer	Officer	2 000 Value: $33.4K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Hansen Gwenn Chief Scientific Officer	Officer	3 750 Value: $62.6K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Hansen Gwenn Chief Scientific Officer	Officer	2 000 Value: $33.4K
Apr 30, 2026 Buy	Restricted Stock Units M-Exempt	Hansen Gwenn Chief Scientific Officer	Officer	2 858 Value: $47.7K
Apr 30, 2026 Buy	Common Stock M-Exempt	Van Houte Hans Chief Financial Officer	C-Suite Officer	2 858 Value: $47.7K
Apr 30, 2026 Sell	Common Stock S-Sale	Van Houte Hans Chief Financial Officer	C-Suite Officer	2 388 Value: $39.7K
Apr 30, 2026 Buy	Common Stock M-Exempt	Van Houte Hans Chief Financial Officer	C-Suite Officer	3 750 Value: $62.6K
Apr 30, 2026 Buy	Common Stock M-Exempt	Van Houte Hans Chief Financial Officer	C-Suite Officer	2 000 Value: $33.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NURIX THERAPEUTICS, INC.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig...

Read Full Profile Here